The Talinolol Double-Peak Phenomenon Is Likely Caused by Presystemic Processing After Uptake from Gut Lumen

Purpose.Evaluation of the double-peak phenomenon during absorption of the β1-selective blocker talinolol relative to paracetamol, which is well absorbed from all parts of the gut, and relative to vitamin A, which is absorbed via the lymphatic pathway.Methods.Talinolol was given with paracetamol and retinyl palmitate in fast-disintegrating, enteric-coated, and rectal soft capsules to 8 fasting male healthy subjects (21–29 years, 68–86 kg). To evaluate whether the talinolol double-peak is associated with processes of food absorption, a breakfast was served 1 h after administration of a fast disintegrating capsule.Results.Bioavailability of talinolol in enteric-coated and rectal capsules was significantly reduced by about 50% and 80%, respectively, despite unchanged bioavailability of paracetamol. Double-peaks appeared after 2–3 h and 4–6 h with talinolol given as fast-liberating capsules. Food increased the maximum concentrations significantly (223 ± 76 μg/ml vs. 315 ± 122 μg/ml, p ‹ 0.05) and shifted the second peak of talinolol to shorter tmax values (3.8 ± 1.2 h vs. 2.1 ± 0.6 h, p ‹ 0.05), which was associated with faster absorption of retinyl palmitate. Pharmacokinetic model fits showed that about half of the oral talinolol dose given with and without meal is drained from the intestine via a presystemic storage compartment.Conclusions.The double-peak phenomenon of talinolol is likely caused by a presystemic storage compartment, which represents the complex interplay of heterogeneous uptake and kick-back transport processes along the intestinal-hepatic absorption pathway.

[1]  A. Breckenridge,et al.  Pharmacokinetics of halofantrine in man: effects of food and dose size. , 1989, British journal of clinical pharmacology.

[2]  H. Lennernäs,et al.  Intestinal drug absorption during induced net water absorption in man; a mechanistic study using antipyrine, atenolol and enalaprilat. , 1994, British journal of clinical pharmacology.

[3]  R. Oertel,et al.  Intestinal secretion of intravenous talinolol is inhibited by luminal R‐verapamil , 1999, Clinical pharmacology and therapeutics.

[4]  M Zschiesche,et al.  Oral bioavailability of digoxin is enhanced by talinolol: Evidence for involvement of intestinal P‐glycoprotein , 2000, Clinical pharmacology and therapeutics.

[5]  H. Koepsell Polyspecific organic cation transporters: their functions and interactions with drugs. , 2004, Trends in pharmacological sciences.

[6]  Gordon L. Amidon,et al.  Celiprolol double-peak occurrence and gastric motility: Nonlinear mixed effects modeling of bioavailability data obtained in dogs , 1995, Journal of Pharmacokinetics and Biopharmaceutics.

[7]  T. Murakami,et al.  Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds. , 1999, The Journal of pharmacology and experimental therapeutics.

[8]  B. Hirst,et al.  The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[9]  J. Lin,et al.  Pharmacokinetic and Pharmacodynamic Properties of Histamine H2-Receptor Antagonists , 1991, Clinical pharmacokinetics.

[10]  Liang-Shang Gan,et al.  Mechanism of Intestinal Absorption of Ranitidine and Ondansetron: Transport Across Caco-2 Cell Monolayers , 1993, Pharmaceutical Research.

[11]  W. Kirch,et al.  Unexpected effect of verapamil on oral bioavailability of the β‐blocker talinolol in humans , 1999 .

[12]  Patrick J. Sinko,et al.  Characterization of the Regional Intestinal Kinetics of Drug Efflux in Rat and Human Intestine and in Caco-2 Cells , 1998, Pharmaceutical Research.

[13]  Yves Plusquellec,et al.  A double-peak phenomenon in the pharmacokinetics of veralipride after oral administration: A double-site model for drug absorption , 1987, Journal of Pharmacokinetics and Biopharmaceutics.

[14]  Honghui Zhou Pharmacokinetic Strategies in Deciphering Atypical Drug Absorption Profiles , 2003, Journal of clinical pharmacology.

[15]  S. Mostafavi,et al.  Influence of cimetidine co-administration on the pharmacokinetics of acebutolol enantiomers and its metabolite diacetolol in a rat model: the effect of gastric pH on double-peak phenomena. , 2003, International journal of pharmaceutics.

[16]  E. Harrison,et al.  Mechanisms involved in the intestinal digestion and absorption of dietary vitamin A. , 2001, The Journal of nutrition.

[17]  H. Akaike A new look at the statistical model identification , 1974 .

[18]  Michael Zschiesche,et al.  Induction of P‐glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: A new type of drug/drug interaction , 2000, Clinical pharmacology and therapeutics.

[19]  K. Bleasby,et al.  The organic cation transporter OCT2 mediates the uptake of β‐adrenoceptor antagonists across the apical membrane of renal LLC‐PK1 cell monolayers , 2000, British journal of pharmacology.

[20]  E. Näslund Gastric Emptying: Comparison of Scintigraphic, Polyethylene Glycol Dilution, and Paracetamol Tracer Assessment Techniques , 2000, Scandinavian journal of gastroenterology.

[21]  Michael Zschiesche,et al.  Carbamazepine regulates intestinal P‐glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans , 2004, Clinical pharmacology and therapeutics.

[22]  U. Klotz,et al.  Site-dependent small intestinal absorption of ranitidine , 2004, European Journal of Clinical Pharmacology.

[23]  K. Giacomini,et al.  Stereoselective Interactions of Organic Cations with the Organic Cation Transporter in OK Cells , 1993, Pharmaceutical Research.

[24]  A. Schinkel,et al.  Pharmacological and Physiological Functions of the Polyspecific Organic Cation Transporters: OCT1, 2, and 3 (SLC22A1-3) , 2004, Journal of Pharmacology and Experimental Therapeutics.

[25]  P. Neuvonen,et al.  High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). , 2004, Pharmacogenetics.

[26]  C. Porter,et al.  Intestinal lymphatic drug transport: an update. , 2001, Advanced drug delivery reviews.

[27]  H. Kroemer,et al.  Stereoselective disposition of talinolol in man. , 2002, Journal of pharmaceutical sciences.

[28]  Gordon L. Amidon,et al.  The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon , 1987, Journal of Pharmacokinetics and Biopharmaceutics.

[29]  T. Gramatté,et al.  Paracetamol absorption from different sites in the human small intestine. , 1994, British journal of clinical pharmacology.

[30]  M. Paine,et al.  P-Glycoprotein Increases from Proximal to Distal Regions of Human Small Intestine , 2003, Pharmaceutical Research.

[31]  K. Wasan The Role of Lymphatic Transport in Enhancing Oral Protein and Peptide Drug Delivery , 2002, Drug development and industrial pharmacy.

[32]  J. Satsangi,et al.  Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease? , 2003, Gut.

[33]  W. Kirch,et al.  P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. , 2000, International journal of clinical pharmacology and therapeutics.

[34]  W. Kirch,et al.  Direct demonstration of small intestinal secretion and site‐dependent absorption of the β‐blocker talinolol in humans , 1996, Clinical pharmacology and therapeutics.

[35]  I. Wilding,et al.  In Vivo Evaluation of Enteric-Coated Naproxen Tablets Using Gamma Scintigraphy , 1992, Pharmaceutical Research.

[36]  H. Kroemer,et al.  Effect of levothyroxine administration on intestinal P‐glycoprotein expression: Consequences for drug disposition * , 2002, Clinical pharmacology and therapeutics.

[37]  Hans Lennernäs,et al.  Evidence for an Interaction Between the β-Blocker Pafenolol and Bile Salts in the Intestinal Lumen of the Rat Leading to Dose-Dependent Oral Absorption and Double Peaks in the Plasma Concentration–Time Profile , 1993, Pharmaceutical Research.

[38]  M. Parkes,et al.  Mobilisation of enterocyte fat stores by oral glucose in humans , 2003, Gut.

[39]  B. Terhaag,et al.  The biliary elimination of the selective beta-receptor blocking drug talinolol in man. , 1989, International journal of clinical pharmacology, therapy, and toxicology.

[40]  R. Oertel,et al.  Disposition and bioavailability of the β1‐adrenoceptor antagonist talinolol in man , 1995, Biopharmaceutics & drug disposition.

[41]  C. Beglinger,et al.  Relevance of p‐glycoprotein for the enteral absorption of cyclosporin A: in vitro‐in vivo correlation , 1996, British journal of pharmacology.

[42]  S. Chetyrkin [Transport and metabolism of vitamin A]. , 2000, Ukrains'kyi biokhimichnyi zhurnal.

[43]  M. J. Story,et al.  Reduced bioavailability of atenolol in man : the role of bile acids , 1993 .

[44]  Michael S. Roberts,et al.  Enterohepatic Circulation , 2002, Clinical pharmacokinetics.

[45]  Kim L. R. Brouwer,et al.  The Complexities of Hepatic Drug Transport: Current Knowledge and Emerging Concepts , 2004, Pharmaceutical Research.

[46]  Panos Macheras,et al.  Gastrointestinal Drug Absorption: Is It Time to Consider Heterogeneity as Well as Homogeneity? , 1997, Pharmaceutical Research.

[47]  Steffen Bauer,et al.  Evidence for Inverse Effects of OATP‐C (SLC21A6) *5 and *1b Haplotypes on Pravastatin Kinetics , 2004, Clinical pharmacology and therapeutics.

[48]  P. Langguth,et al.  Evidence for Intestinal Secretion as an Additional Clearance Pathway of Talinolol Enantiomers: Concentration- and Dose-dependent Absorption in Vitro and in Vivo , 1996, Pharmaceutical Research.

[49]  G. Warhurst,et al.  Region-Dependent Modulation of Intestinal Permeability by Drug Efflux Transporters: In Vitro Studies in mdr1a(−/−) Mouse Intestine , 2002, Journal of Pharmacology and Experimental Therapeutics.

[50]  J. Nezu,et al.  Involvement of Human Organic Anion Transporting Polypeptide OATP-B (SLC21A9) in pH-Dependent Transport across Intestinal Apical Membrane , 2003, Journal of Pharmacology and Experimental Therapeutics.

[51]  K. Johnson An Update. , 1984, Journal of food protection.

[52]  W. H. Barr,et al.  Absorption of Danazol After Administration to Different Sites of the Gastrointestinal Tract and the Relationship to Single‐ and Double‐Peak Phenomena in the Plasma Profiles , 1993, Journal of clinical pharmacology.

[53]  P. Tso,et al.  Vitamin A uptake from foods , 2003, Current opinion in lipidology.